Is Trident Texofab overvalued or undervalued?

As of 22 August 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive. This indicates that the company is currently overvalued. Key ratios highlight this valuation concern, with a PE ratio of 122.14, an EV to EBITDA of 70.73, and a PEG ratio of 5.80, all significantly higher than typical industry benchmarks.
When compared to peers, Trident Texofab's valuation stands out unfavorably. For instance, Lloyds Enterprises has a PE ratio of 39 and an EV to EBITDA of 96.38, while PTC India, which is categorized as very attractive, boasts a PE of just 8.95. Additionally, Trident Texofab's recent stock performance has been impressive, with a one-year return of 426.35%, significantly outpacing the Sensex's return of 0.31%. However, despite this strong performance, the high valuation metrics suggest that the stock may not be a prudent investment at current levels.